CMTM3抗体—艾普蒂

+ +

•  

   

     Gel: 10+12%SDS-PAGE, Lysate: 40 μg, Lane: 231 cells, Primary antibody: P03965(CMTM3 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P03965(CMTM3 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P03965(CMTM3 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

CMTM3 (CKLF-like MARVEL transmembrane domain-containing protein 3) is a member of the chemokine-like factor (CKLF) superfamily, characterized by a conserved MARVEL domain involved in membrane trafficking and cell junction organization. This protein is widely expressed in human tissues, particularly immune cells, and plays roles in immune regulation, cell proliferation, and apoptosis. CMTM3 has been identified as a tumor suppressor, with studies showing its frequent downregulation in cancers like hepatocellular carcinoma, gastric cancer, and non-small cell lung cancer. Epigenetic silencing via promoter hypermethylation is a key mechanism behind its reduced expression in malignancies.

Antibodies targeting CMTM3 are essential tools for investigating its expression patterns, interactions, and functional mechanisms in both physiological and pathological contexts. They enable detection of CMTM3 in Western blotting, immunohistochemistry, and immunofluorescence, aiding research into its tumor-suppressive pathways, such as modulating EGFR/HER2 signaling or inhibiting epithelial-mesenchymal transition. CMTM3 antibodies also hold potential for developing diagnostic biomarkers or therapeutic strategies targeting CMTM3-related pathways in cancer and immune disorders. However, specificity validation remains critical due to homology within the CMTM family.